Regeneron won an FDA approval for Otarmeni, a gene therapy targeting a rare inherited form of hearing loss. The approval is notable as the first gene therapy cleared under the agency’s national priority voucher program, and Regeneron said it will offer the treatment at no cost to eligible U.S. patients. The therapy is aimed at an ultra-rare genetic mutation found in an estimated 50 newborns per year. As part of the voucher framework, the approval also comes with a rare pediatric disease priority review voucher that Regeneron can monetize—an element likely to affect future incentives for gene-therapy sponsors. Clinically, the decision provides a new pathway for treating genetic hearing loss and adds another precedent for the FDA’s voucher strategy. It also raises questions for competitors about how quickly similar programs may converge around single-enzyme or single-mutation genetic targets.